Analysts’ Weekly Ratings Updates for Abivax (ABVX)

Abivax (NASDAQ: ABVX) recently received a number of ratings updates from brokerages and research firms:

• 10/21/2026 – Abivax had its “overweight” rating reaffirmed by Piper Sandler.
• 10/21/2026 – Abivax had its price target lowered by Wedbush from $118.00 to $96.00. They now have a “neutral” rating on the stock.
• 10/20/2026 – Abivax had its “buy” rating reaffirmed by Guggenheim. They now have a $175.00 price target on the stock.
• 10/15/2026 – Abivax had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/26/2026 – Abivax was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/22/2026 – Abivax had its price target lowered by Truist Financial from $155.00 to $151.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Abivax had its price target lowered by Wedbush from $140.00 to $118.00. They now have a “neutral” rating on the stock.
• 9/22/2026 – Abivax had its “overweight” rating reaffirmed by Barclays. They now have a $148.00 price target on the stock.
• 9/9/2026 – Abivax is now covered by The Goldman Sachs Group. They set a “buy” rating and a $155.00 price target on the stock.
• 9/9/2026 – Abivax was upgraded by The Goldman Sachs Group to “strong-buy”.

Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.

Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.